{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075175","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.959122+00:00","generated_at":"2026-05-17T17:20:37.677594+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026","bullets":["Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.","Reiterated FY2025 total product revenue guidance of $250M-$300M.","Appointed Corleen Roche as CFO, effective after Q2 10-Q filing, replacing Matthew Rosinack.","Strategic restructuring reduces workforce by 19%, generating over $100M annual savings, extending cash runway into Q4 2026.","Over 100 patients treated with Amtagvi in Q2; network includes over 80 ATCs across 35 states."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075175","json":"https://secwatch.observer/filing/0001104659-25-075175.json","markdown":"https://secwatch.observer/filing/0001104659-25-075175.md","text":"https://secwatch.observer/filing/0001104659-25-075175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/0001104659-25-075175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T17:20:37.677594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}